Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Celgene

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Celgene's 2013 oncology sales performance.

Celgene

HTA guidance from NICE, the SMC and the AWMSG

Celgene has scored a positive recommendation from England’s cost-effectiveness watchdog NICE for Revlimid in follicular lymphoma, chalking up another indication.

Switzerland: a life sciences hub

Switzerland: a life sciences hub Celgene, now a subsidiary of Bristol-Myers Squibb (BMS), recently built its second production plant in Couvet, followed by the construction of a third production site in Boudry (Neuchâtel), to produce

Janssen scores another expansion for new Darzalex combination in the US

Janssen scores another expansion for new Darzalex combination in the US It also has an approval for another combination regimen made up of Darzalex, Celgene’s Revlimid (lenalidomide) and dexamethasone, for the treatment of newly diagnosed multiple myeloma patients who are ineligible

BMS pays $475m for Dragonfly’s IL-12 immunotherapy programme

BMS pays $475m for Dragonfly’s IL-12 immunotherapy programme Dragonfly also signed a deal with Celgene, now owned by BMS, in 2017 and 2018 for a series of candidates focused on the treatment of blood cancers.

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

Bristol-Myers Squibb’s revenues rise on Celgene acquisition The increase, said BMS, was primarily driven by the impact products gained from its acquisition of Celgene, which completed in November 2019. ... BMS’ biggest seller was its multiple myeloma therapy Revlimid (lenalidomide), which it added to its

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics